SCHEMBL6585537

SCHEMBL6585537

N#Cc1ccc(S(=O)(=O)C2CCN(CC(=O)c3ccc(F)cc3)CC2)cc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 7/20 0.73
HTR2C P28335 6/20 0.73
KCNH2 Q12809 6/20 0.73
DRD2 P14416 2/20 0.56
PRKAA2 P54646 3/20 0.53
POLB P06746 1/20 0.49
ALDH1A1 P00352 3/20 0.47
GAA P10253 2/20 0.47
TSHR P16473 2/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2D6 P10635 1/20 0.47
PKM P14618 1/20 0.47
ALOX15 P16050 1/20 0.47
CYP2C19 P33261 1/20 0.47
SIGMAR1 Q99720 1/20 0.46
KDM4E B2RXH2 2/20 0.45
MAPT P10636 1/20 0.45
RECQL P46063 1/20 0.45
NSD2 O96028 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6585664 0.85 HTR2A (0.78) HTR2AHTR2CKCNH2DRD2ALDH1A1
SCHEMBL6583840 0.85 HTR2A (1.00) HTR2AHTR2CKCNH2DRD2ALDH1A1
SCHEMBL5216044 0.80 HTR2A (0.60) HTR2AHTR2CKCNH2DRD2POLB
SCHEMBL7030971 0.80 HTR2A (0.73) HTR2AHTR2CKCNH2DRD2PRKAA2
SCHEMBL1121499 0.79 GRIN2B (0.46) HTR2AHTR2CKCNH2POLBALDH1A1
SCHEMBL28214351 0.76 HTR2A (0.63) HTR2AHTR2CKCNH2DRD2PRKAA2
SCHEMBL6586485 0.74 HTR2A (1.00) HTR2AHTR2CKCNH2DRD2
SCHEMBL20002690 0.74 PRKAA2 (0.50) HTR2AHTR2CKCNH2PRKAA2POLB
SCHEMBL8430052 0.73 SIGMAR1 (0.61) POLBALDH1A1SIGMAR1KDM4EMAPT
SCHEMBL16632052 0.73 HTR2A (0.49) HTR2AHTR2CKCNH2PRKAA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1147084-B1 PHENYLSULPHONYL DERIVATIVES AS 5-HT RECEPTOR LIGANDS MERCK SHARP & DOHME (GB) 2004-05-19 EP claimed
US-20030203889-A1 Phenylsulphonyl derivatives as 5-HT receptor ligands MERCK & CO., INC. 2003-10-30 US claimed
US-6559166-B1 A class of phenylsulphonyl derivatives wherein the sulphonyl moiety is also attached to an N-arylalkyl-substituted azetidine, pyrrolidine or piperidine ring are selective antagonists of the human 5-HT2A receptor and are therefore MERCK SHARP & DOHME LTD. 2003-05-06 US claimed
EP-1147084-A1 PHENYLSULPHONYL DERIVATIVES AS 5-HT RECEPTOR LIGANDS MERCK SHARP & DOHME LTD. (GB) 2001-10-24 EP claimed
WO-2000043362-A1 PHENYLSULPHONYL DERIVATIVES AS 5-HT RECEPTOR LIGANDS MERCK SHARP & DOHME LIMITED (GB) 2000-07-27 WO claimed
US-6777430-B2 A DERIVATIVES WITH ATTACHED TO AN N-ARYLALKYL-SUBSTITUTED AZETIDINE, PYRROLIDINE OR PIPERIDINE RING; A SERATONIN RECEPTOR ANTAGONISTS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDER SCHIZOPHRENIA, DEPRESSION MERCK SHARP & DOHME LTD. 2004-08-17 US disclosed
EP-1147084-B1 PHENYLSULPHONYL DERIVATIVES AS 5-HT RECEPTOR LIGANDS MERCK SHARP & DOHME (GB) 2004-05-19 EP disclosed
US-20030203889-A1 Phenylsulphonyl derivatives as 5-HT receptor ligands MERCK & CO., INC. 2003-10-30 US disclosed
US-6559166-B1 A class of phenylsulphonyl derivatives wherein the sulphonyl moiety is also attached to an N-arylalkyl-substituted azetidine, pyrrolidine or piperidine ring are selective antagonists of the human 5-HT2A receptor and are therefore MERCK SHARP & DOHME LTD. 2003-05-06 US disclosed
EP-1147084-A1 PHENYLSULPHONYL DERIVATIVES AS 5-HT RECEPTOR LIGANDS MERCK SHARP & DOHME LTD. (GB) 2001-10-24 EP disclosed
WO-2000043362-A1 PHENYLSULPHONYL DERIVATIVES AS 5-HT RECEPTOR LIGANDS MERCK SHARP & DOHME LIMITED (GB) 2000-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030203889-A1 Phenylsulphonyl derivatives as 5-HT receptor ligands HTR2A, HTR5A, HTR2C HTR2A 1/4885HTR2C 3/4885KCNH2 461/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.